Back to Mobile View

Investing

When Nuance Communications (NAS: NUAN) lined up for this week's first-quarter report, I expected a blowout. Fellow Fool Evan Niu was so excited, he started a real-money options position on the stock with a $34 break-even point. That's about a 13% premium to Thursday's closing price, so Evan...
Diamond Foods (NAS: DMND) may have blown its biggest deal to date. The maker of Emerald nuts and Pop Secret popcorn recently ousted its CEO and CFO after an internal audit exposed improper payments to walnut growers. Diamond will need to restate the past two years of financials and it...
The following video is part of our "Motley Fool Conversations" series, in which senior analyst Anand Chokkavelu, CFA, discusses topics across the investing world.Until the financial crisis hit, Citigroup was a proud Dow component. Anand discusses whether it should be again....
When a company forecasts lower sales or profits, its stock usually takes a hit. It's not always easy to tell whether your company is having a fire sale or it's burning down. Maybe it's time to get out -- or maybe it's time to buy more! To help tell the difference, we pair up the dour guidance...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of movie studio Lions Gate Entertainment (NYS: LGF) were getting cheers from...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of First Solar (NAS: FSLR) slid as much as 11% today after the company said it...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of denim demigod True Religion (NAS: TRLG) were getting thrown in the dirty-clothes...
Mark your calendars, biotech investors. Two obesity drugs are up for review by Food and Drug Administration advisory panels in the coming months. Both VIVUS' (NAS: VVUS) Qnexa and Arena Pharmaceuticals' (NAS: ARNA) lorcaserin were turned down by the FDA in October 2010. But the companies...
I get goose bumps when I ponder the profits that Thompson Creek Metals (NYS: TC) will enjoy once the Mt. Milligan copper and gold mine initiates production during the second half of 2013. Despite a quick 37% advance since I suggested a few months ago that the downtrodden stock offered exposure...
Momenta Pharmaceuticals (NAS: MNTA) registered its second year of profitability last year. The biotech brought in $283 million in revenue last year, and since its partner Novartis (NYS: NVS) covers the sales and manufacturing of enoxaparin -- their generic version of Sanofi's (NYS:...

Buy Stocks At...

Newswire

Follow Us

Compare Mortgage Rates

Mortgage Rates by Zillow

Headlines From DailyFinance Partners

CNN Money
CNBC
Smart Money
Consumer Reports
Huffington Post
AOL Energy
AOL Jobs
Business News Personal Finance Investing Our Partners

DailyFinance Sitemap | Terms of Service | Privacy Policy | Trademarks | HELP | Advertise With Us

© Copyright 2012 AOL Inc. All Rights Reserved